Nasdaq
$1.93▲ 0.52%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $58.8MShares out 30.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 10.2Regular26.10.03 00:14ARSOther#●●●
XBiotech Inc.
XBiotech Inc. filed its Annual Report to Security Holders (ARS) on October 2, 2026. This filing provides the annual business and financial status update to the company's shareholders.…more
$1.93+0.52%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2Regular26.10.03 00:13DEF 14AOther
XBiotech Inc.
XBiotech will hold its 2026 Annual Meeting of Shareholders on November 24, 2026, to vote on the election of five directors, the ratification of Whitley Penn LLP as the independent auditor, and advisory approval of executive compensation. Only shareholders of record as of September 25, 2026, are entitled to vote, representing 30,487,731 outstanding shares of common stock.…more
$1.93+0.52%vs prev closeView filingShare - 8.13Regular26.08.14 00:2610-QEarnings
XBiotech Inc.
XBiotech reported an operating loss of $6.146 million for the second quarter of 2026. As of June 30, 2026, the company held $109.528 million in cash and cash equivalents, with 30,487,731 shares of common stock issued and outstanding.…more
$1.93+0.52%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 22h agoClosed26.10.24 21:07#●●●#●●●
XBiotech Appoints Sushma Shivaswamy and Jan-Paul Simard as Co-CEOs
XBiotech has announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers. This leadership change is intended to strengthen the company's operational continuity and advance its antibody therapy pipeline.…more
$1.93+0.52%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 1d agoPre-market26.10.23 22:17
●●●●●●●● ●●●●● ●●●●●●
XBiotech has announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers. This leadership change aims to enhance the company's operational continuity and advance its antibody therapy pipeline.…more
$1.93+0.52%vs prev close - 5d agoAfter-hours26.10.20 07:59
●●●●●●●● ●●●●● ●●●●●●
XBiotech announced that its Phase II trial for refractory metastatic colorectal cancer met its primary efficacy endpoint, showing improved survival rates. However, as the significant benefits were observed in exploratory subgroup analyses, further clinical development is required.…more
$1.93+0.52%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report